amorchem header logo close button Menu
arrow leftBack to portfolio


This program is focused on validating an antibody against a novel target for chronic inflammation, the S100A9 protein. Results show that blocking S100A9 has an equivalent effect on inflammation to blocking TNF-α, a clinically-validated target. The optimized antibody will be validated in relevant animal models. This program originates from the laboratory of Dr. Philippe Tessier (Université Laval) and his spin-off company, InflammatoRx, and is currently under option by a pharmaceutical company.